Exelixis
EXEL
#1817
Rank
HK$92.08 B
Marketcap
HK$343.48
Share price
-0.48%
Change (1 day)
25.92%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2024: HK$16.83 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is HK$17.88 Billion. In 2024 the company made a revenue of HK$16.83 Billion an increase over the revenue in the year 2023 that were of HK$14.29 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2024

Annual revenue

Year Revenue Change
2024HK$16.83 B17.79%
2023HK$14.29 B13.56%
2022HK$12.58 B12.5%
2021HK$11.18 B46.16%
2020HK$7.65 B1.57%
2019HK$7.53 B12.73%
2018HK$6.68 B89.13%
2017HK$3.53 B138.12%
2016HK$1.48 B415.3%
2015HK$0.28 B47.92%
2014HK$0.19 B-19.85%
2013HK$0.24 B-33.93%
2012HK$0.36 B-83.65%
2011HK$2.24 B56.21%
2010HK$1.44 B22.38%
2009HK$1.17 B29.2%
2008HK$0.91 B2.94%
2007HK$0.88 B15.29%
2006HK$0.76 B30.3%
2005HK$0.58 B43.38%
2004HK$0.41 B2.82%
2003HK$0.39 B15.58%
2002HK$0.34 B8.1%
2001HK$0.31 B65.58%
2000HK$0.19 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Johnson & Johnson
JNJ
HK$720.15 B 3,927.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$490.68 B 2,643.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$281.11 B 1,472.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$371.41 B 1,976.95%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$502.00 B 2,707.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$375.39 B 1,999.19%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$330.99 B 1,750.91%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
HK$91.04 M-99.49%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
HK$0.73 B-95.88%๐Ÿ‡บ๐Ÿ‡ธ USA